However, methylated SEPT9 has also been studied in a screening population as part of the PRESEPT trial in the USA and Germany, showing overall sensitivity of 48.2% and specificity of 91.5% for detecting CRC [30]. The gene discussed is SEPTIN9; the disease is colorectal carcinoma.